Abbvie (ABBV)

Company Profile

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Company profile

Ticker

ABBV

Exchange

NYSE

Website

www.abbvie.com

CEO

Richard Gonzalez

Incorporated

Delaware

Location

Illinois

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Celgene • Royalty Pharma ...

SEC CIK

0001551152

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

AbbVie Aviation LLC • AbbVie Biopharmaceuticals LLC • AbbVie Bioresearch Center Inc. • AbbVie Biotech Ventures Inc. • AbbVie Biotherapeutics Inc. • AbbVie Domestic Holdings Inc. • AbbVie Endocrine Inc. • AbbVie Endocrinology Inc. • AbbVie Finance Corporation • AbbVie Finance LLC ...

IRS number

320375147

ABBV stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$160.67

Low target

$135.00

High target

$178.00

Latest filings (excl ownership)

View all

8-K

Departure of Directors or Certain Officers

29 Nov 22

S-8

Registration of securities for employees

4 Nov 22

AbbVie Reports Third-Quarter 2022 Financial Results

Departure of Directors or Certain Officers

17 Oct 22

8-K

Departure of Directors or Certain Officers

14 Oct 22

8-K

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

5 Oct 22

CORRESP

Correspondence with SEC

Transcripts

View all

ABBV

Earnings call transcript

2022 Q3

28 Oct 22

ABBV

Earnings call transcript

2022 Q2

29 Jul 22

ABBV

Earnings call transcript

2022 Q1

29 Apr 22

ABBV

Earnings call transcript

2021 Q4

2 Feb 22

ABBV

Earnings call transcript

2021 Q3

29 Oct 21

ABBV

Earnings call transcript

2021 Q2

30 Jul 21

ABBV

Earnings call transcript

2021 Q1

30 Apr 21

ABBV

Earnings call transcript

2020 Q4

4 Feb 21

ABBV

Earnings call transcript

2020 Q3

30 Oct 20

ABBV

Earnings call transcript

2020 Q2

31 Jul 20

Latest ownership filings

View all

Annual report of employee stock purchases

23 Jun 22

11-K

Annual report of employee stock purchases

Financial summary

Financial statements Chart ABBV financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	11.83 bn	11.83 bn	11.83 bn	11.83 bn	11.83 bn	11.83 bn
Cash burn (monthly)	(no burn)	29.17 mm	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	n/a	63.92 mm	n/a	n/a	n/a	n/a
Cash remaining	n/a	11.77 bn	n/a	n/a	n/a	n/a
Runway (months of cash)	n/a	403.5	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from Abbvie earnings reports.

Institutional ownership, Q3 2022

ABBV institutional ownership history Ownership history

62.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2781	2848	-2.4%
Opened positions	123	138	-10.9%
Closed positions	190	175	+8.6%
Increased positions	1215	1082	+12.3%
Reduced positions	1084	1249	-13.2%

13F shares	Current	Prev Q	Change
Total value	148.85 bn	181.81 bn	-18.1%
Total shares	1.11 bn	1.19 bn	-6.7%
Total puts	10.96 mm	12.66 mm	-13.4%
Total calls	14.02 mm	15.48 mm	-9.4%
Total put/call ratio	0.8	0.8	-4.5%

Largest owners	Shares	Value	Change
Vanguard	156.02 mm	$20.94 bn	+1.6%
BLK Blackrock	132.96 mm	$17.84 bn	-1.3%
JPM JPMorgan Chase & Co.	58.48 mm	$7.85 bn	+4.2%
Capital International Investors	45.83 mm	$6.15 bn	+6.2%
Capital Research Global Investors	36.19 mm	$4.86 bn	+37.6%
Geode Capital Management	33.83 mm	$4.54 bn	+12.5%
MS Morgan Stanley	26.79 mm	$3.60 bn	+2.7%
T. Rowe Price	24.52 mm	$3.29 bn	-20.4%
NTRS Northern Trust	21.85 mm	$2.93 bn	-1.4%
BK Bank Of New York Mellon	20.69 mm	$2.78 bn	-2.8%

Largest transactions	Shares	Bought/sold	Change
STT State Street	0.00	-77.12 mm	EXIT
Capital Research Global Investors	36.19 mm	+9.90 mm	+37.6%
T. Rowe Price	24.52 mm	-6.29 mm	-20.4%
Geode Capital Management	33.83 mm	+3.75 mm	+12.5%
GQG Partners	44.41 k	-3.01 mm	-98.5%
Capital International Investors	45.83 mm	+2.67 mm	+6.2%
Vanguard	156.02 mm	+2.44 mm	+1.6%
FMR	15.02 mm	-2.39 mm	-13.7%
JPM JPMorgan Chase & Co.	58.48 mm	+2.37 mm	+4.2%
Allianz Asset Management GmbH	1.76 mm	-2.26 mm	-56.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ABBV insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Sep 22	Alpern Robert J	Stock Equivalent Units Common Stock	Grant	Acquire A	No	No	134.21	55	7.38 k	8,598
30 Sep 22	Edward J Rapp	Stock Equivalent Units Common Stock	Grant	Acquire A	No	No	134.21	288	38.65 k	22,806
30 Jun 22	Edward J Rapp	Stock Equivalent Units Common Stock	Grant	Acquire A	No	No	153.16	237	36.30 k	22,296
30 Jun 22	Alpern Robert J	Stock Equivalent Units Common Stock	Grant	Acquire A	No	No	153.16	47	7.20 k	8,458